Neuron23, Inc.
Neuron23 is a biotechnology company dedicated to developing precision medicines for genetically defined neurological and immunological diseases. Using advanced data science, human genetics, and AI-enabled drug discovery platforms, the company aims to create targeted therapies for devastating diseases such as Parkinson's, multiple sclerosis, and systemic autoimmune and inflammatory diseases. Founded in 2018 and based in South San Francisco, CA, Neuron23 is committed to transforming treatment approaches through innovation, collaboration, and a patient-centric mission.
Industries
Nr. of Employees
small (1-50)
Products
NEU-411 (LRRK2 inhibitor)
Oral, brain-penetrant small-molecule inhibitor targeting LRRK2 developed for LRRK2-driven Parkinson’s disease; evaluated in Phase 1 and being studied in a global Phase 2 trial with biomarker and digital endpoints.
NEU-111 (peripherally restricted TYK2 inhibitor)
Oral allosteric TYK2 inhibitor designed to reduce peripheral immune signaling with Phase 1 clinical evaluation for safety, tolerability, and pharmacokinetics.
NEU-627 (central TYK2 inhibitor)
Preclinical highly potent brain-penetrant TYK2 inhibitor advanced for multiple sclerosis and other neuroinflammatory diseases.
NEU-723 (LRRK2 inhibitor; earlier clinical candidate)
Brain-penetrant LRRK2 inhibitor that entered First-in-Human Phase 1 testing; part of the LRRK2 discovery portfolio.
NGS-based companion diagnostic assay (investigational)
Blood-based next-generation sequencing assay and predictive algorithm intended to identify patients with genetic signatures (SNP panel and model) consistent with elevated pathway activity and likely response to LRRK2-targeted therapy.
NEU-411 (LRRK2 inhibitor)
Oral, brain-penetrant small-molecule inhibitor targeting LRRK2 developed for LRRK2-driven Parkinson’s disease; evaluated in Phase 1 and being studied in a global Phase 2 trial with biomarker and digital endpoints.
NEU-111 (peripherally restricted TYK2 inhibitor)
Oral allosteric TYK2 inhibitor designed to reduce peripheral immune signaling with Phase 1 clinical evaluation for safety, tolerability, and pharmacokinetics.
NEU-627 (central TYK2 inhibitor)
Preclinical highly potent brain-penetrant TYK2 inhibitor advanced for multiple sclerosis and other neuroinflammatory diseases.
NEU-723 (LRRK2 inhibitor; earlier clinical candidate)
Brain-penetrant LRRK2 inhibitor that entered First-in-Human Phase 1 testing; part of the LRRK2 discovery portfolio.
NGS-based companion diagnostic assay (investigational)
Blood-based next-generation sequencing assay and predictive algorithm intended to identify patients with genetic signatures (SNP panel and model) consistent with elevated pathway activity and likely response to LRRK2-targeted therapy.
Services
Clinical trial design and execution
Design and run randomized, double-blind, placebo-controlled clinical studies incorporating biomarker-driven patient selection and digital endpoints.
Companion diagnostic development and validation (NGS-based)
Co-development and validation of blood-based NGS assays and predictive algorithms to detect genetic signatures that predict therapeutic responsiveness.
Biomarker discovery and translational research
Identification and validation of translational biomarkers (including fluid biomarkers and CNS neuroinflammatory markers) and evaluation in preclinical disease models.
AI/ML-driven target discovery and patient stratification
Machine-learning approaches that integrate large genomic datasets to prioritize targets and define patient subpopulations for precision therapies.
Medicinal chemistry and small-molecule discovery
Design and synthesis of selective small-molecule inhibitors optimized for potency, selectivity, and CNS penetration or peripheral restriction depending on indication.
Clinical trial design and execution
Design and run randomized, double-blind, placebo-controlled clinical studies incorporating biomarker-driven patient selection and digital endpoints.
Companion diagnostic development and validation (NGS-based)
Co-development and validation of blood-based NGS assays and predictive algorithms to detect genetic signatures that predict therapeutic responsiveness.
Biomarker discovery and translational research
Identification and validation of translational biomarkers (including fluid biomarkers and CNS neuroinflammatory markers) and evaluation in preclinical disease models.
AI/ML-driven target discovery and patient stratification
Machine-learning approaches that integrate large genomic datasets to prioritize targets and define patient subpopulations for precision therapies.
Medicinal chemistry and small-molecule discovery
Design and synthesis of selective small-molecule inhibitors optimized for potency, selectivity, and CNS penetration or peripheral restriction depending on indication.
Expertise Areas
- Clinical trial management (Phase 1–2)
- Biomarker discovery and translational research
- Precision medicine and patient stratification
- Medicinal chemistry and small-molecule discovery
Key Technologies
- Next-generation sequencing (NGS)
- Machine learning / AI for target discovery and stratification
- Digital biomarkers / smartphone-based monitoring
- Small-molecule kinase inhibition